Trends in amorphous solid dispersion drug products approved by the U.S. FDA between 2012 and 2023

In a recent publication, the trends in ASD drug products over a 12-year period from 2012 to 2023 were analyzed. The review highlights the role of AustinPx’s KinetiSol Technology, a solvent-free process that provides significant advantages over traditional methods like spray drying. KinetiSol’s ability to process thermolabile compounds and improve drug stability and bioavailability is emphasized as a key innovation in the field of amorphous solid dispersions.

The article notes that KinetiSol has been increasingly adopted for its efficiency in scale-up processes and its versatility in handling a wide range of drug formulations. This technology is also noted for addressing common challenges in the pharmaceutical industry, offering a robust solution for developing modern, patient-centric drug products.